Engineered bacterial therapy activates immune response in cancer preclinical studies
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Nov-2025 18:11 ET (5-Nov-2025 23:11 GMT/UTC)
Researchers at MIT and Harvard Medical School found a way to engineer CAR-NK immune cells that makes them much less likely to be rejected by the patient’s immune system, a common drawback of this type of cancer immunotherapy.
Researchers at Leipzig University and Martin Luther University Halle-Wittenberg have investigated a previously unknown process that occurs during protein synthesis in the cell. They examined how so-called adhesion G protein-coupled receptors (aGPCRs) split themselves into two parts. This self-cleavage takes place in a region of the protein known as the GAIN domain, which is considered crucial for the receptor’s ability to detect and transmit signals. The self-cleavage acts as a kind of built-in quality control: only correctly cleaved receptors are allowed to leave the “cell factory” and reach the surface. The study has just been published in the journal Nature Communications.
Some colourful lizards and a mathematical formula from the finance sector have been used to build a new framework to model evolution.